Last reviewed · How we verify
LentiGlobin BB305 Drug Product
LentiGlobin BB305 Drug Product is a Small molecule drug developed by Genetix Biotherapeutics Inc.. It is currently in Phase 1 development.
At a glance
| Generic name | LentiGlobin BB305 Drug Product |
|---|---|
| Sponsor | Genetix Biotherapeutics Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Thrombocytopenia
- Neutropenia
- Anaemia
- Stomatitis
- Vomiting
- Nausea
- Alopecia
- Pyrexia
- Procedural pain
- Alanine aminotransferase increased
- Febrile neutropenia
- Leukopenia
Key clinical trials
- Long-term Follow-up of Subjects With Transfusion-Dependent β-Thalassemia (TDT) Treated With Ex Vivo Gene Therapy
- A Study Evaluating the Safety and Efficacy of Lovo-cel in Severe Sickle Cell Disease (PHASE1, PHASE2)
- A Study Evaluating Gene Therapy With BB305 Lentiviral Vector in Sickle Cell Disease (PHASE3)
- A Study Evaluating the Efficacy and Safety of the LentiGlobin® BB305 Drug Product in Participants With Transfusion-Dependent β-Thalassemia (PHASE3)
- A Study Evaluating the Efficacy and Safety of the LentiGlobin® BB305 Drug Product in Participants With Transfusion-Dependent β-Thalassemia, Who do Not Have a β0/β0 Genotype (PHASE3)
- A Study Evaluating the Safety and Efficacy of LentiGlobin BB305 Drug Product in β-Thalassemia Major (Also Referred to as Transfusion-dependent β-Thalassemia [TDT]) and Sickle Cell Disease (PHASE1, PHASE2)
- A Study Evaluating the Safety and Efficacy of the LentiGlobin BB305 Drug Product in β-Thalassemia Major Participants (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LentiGlobin BB305 Drug Product CI brief — competitive landscape report
- LentiGlobin BB305 Drug Product updates RSS · CI watch RSS
- Genetix Biotherapeutics Inc. portfolio CI
Frequently asked questions about LentiGlobin BB305 Drug Product
What is LentiGlobin BB305 Drug Product?
LentiGlobin BB305 Drug Product is a Small molecule drug developed by Genetix Biotherapeutics Inc..
Who makes LentiGlobin BB305 Drug Product?
LentiGlobin BB305 Drug Product is developed by Genetix Biotherapeutics Inc. (see full Genetix Biotherapeutics Inc. pipeline at /company/genetix-biotherapeutics-inc).
What development phase is LentiGlobin BB305 Drug Product in?
LentiGlobin BB305 Drug Product is in Phase 1.
What are the side effects of LentiGlobin BB305 Drug Product?
Common side effects of LentiGlobin BB305 Drug Product include Thrombocytopenia, Neutropenia, Anaemia, Stomatitis, Vomiting, Nausea.
Related
- Manufacturer: Genetix Biotherapeutics Inc. — full pipeline